scholarly journals AB0247 LIFE QUALITY AND DEPRESSION LEVEL ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1424.2-1424
Author(s):  
T. Janković ◽  
J. Zvekic-Svorcan ◽  
B. Milić ◽  
D. Vukliš ◽  
R. Krasnik ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Pain Intensity ◽  
Life Quality ◽  
Activity Level ◽  
Depression Symptoms ◽  
Global Disease Activity ◽  
Anxiety Depression

Background:Depression is a common and significant rheumatoid arthritis (RA) comorbidity that develops under the influence of severalfactors, the most important being disease activity, pain intensity and degree of disability.Objectives:The goal of the investigation was to determine existence of depression and assess life quality in patients living with RA.Methods:The study sample comprised of 150 patients of average age 59.2 years, 79.2% of whom were women and 20.8% were men, who have lived with RA for an average of 9.6 years. For determining disease activity level, Disease Activity ScoreDAS28was utilized. Pain intensity and global disease activity were rated using a visual analogue scale ranging from 1 to 100mm. For functional capacity assessments, Health Assessment Questionnaire(HAQ) index was adopted,depressions severity was determined through Back Depression Inventory (BDI), and Serbian version of the health-related quality of life instrument EQ-5Dwas employed to assess patients’ quality of life.Results:Average DAS28 score for the sample was4.46±1.32, suggesting moderate RA activity. Pain intensity was on average scored at 53.2±18.6, whereas global disease activity was measured at 49.63±20.2, and theHAQ indexof 1.0±0.70 was obtained. According to theBDI, 21.4% of the patients exhibited no signs of depression, whereas 12.9% had mild, 54.3% moderate, and11.4% severe form of depression.Quality of life, as measured by EQ-5D, was compromised in all life domains, withpain/discomfort, anxiety/depression, inability to partake in usual activities, compromised mobility and self-caremost frequently reported. In patients suffering from moderate and severe depression, high statistically significant positive correlation between depression score and HAQ index was noted.BDIscore was statistically significantly positively correlatedwith the ratings on the EQ-5D scales pertaining to self-care, usual activities, pain/discomfort, and anxiety/depression.Conclusion:Depression symptoms are common in patients with RA and can compromise quality of life in all life domains.When assessing disease severity and general status of patients with RA, depression symptoms should also be considered, given their high prevalence and influence on patients’ everyday life.Acknowledgments:notDisclosure of Interests:None declared

AB0218 FUNCTIONAL DISABILITY AND PAIN BUT NOT DISEASE ACTIVITY ARE ASSOCIATED WITH POOR HEALTH-RELATED QUALITY OF LIFE IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1409.1-1409
Author(s):  
A. R. Prata ◽  
H. Assunção ◽  
M. Luis ◽  
L. Brites ◽  
F. Costa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Poor Health ◽  
Visual Analogue Scale Pain ◽  
Depression Symptoms ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Background:Rheumatoid Arthritis (RA) is a systemic autoimmune disease that presents with joint pain and inflammation leading to significant disability and poor health-related quality of life (HRQoL) (1,2). Optimizing long-term HRQoL is the primary goal of disease management in RA (3).Objectives:To evaluate HRQoL and identify its influencing clinical and demographic factors in a Portuguese RA population.Methods:This is a cross-sectional study including consecutive patients fulfilling the ACR/EULAR 2010 and/or ACR 1987 RA classification criteria, followed at a tertiary Rheumatology Department. Sociodemographic and clinical variables were collected. HRQoL was assessed using the EuroQoL 5-Dimensional Descriptive System (EQ-5D) total score (normal range from -0.496 to 1.000, lower values indicating poorer HRQoL). Independent t-test and Pearson’s correlation coefficient were performed to evaluate EQ-5D differences between groups and examine its relationships with continuous variables, respectively. Variables with p<0.1 in univariate analysis were included in a stepwise multiple linear regression analysis to evaluate the independent association of variables with the EQ-5D score.Results:358 RA patients were included (80.20% female, mean age ± SD: 63.22 ± 0.66 years old). Mean EQ5D total score ±SD was 0.48 ± 0.01. Based on EQ-5D domains, 0.60% reported extreme problems with mobility, 3.40% extreme problems with self-care, 2.50% extreme problems with usual activities, 12.0% extreme pain or discomfort, and 7.30% extreme anxiety or depression symptoms (Fig. 1). There was a significant difference in EQ-5D scores between male (M=0.55, SD=0.24) and female gender (M=0.46, SD= 0.27); t (356) = -2.41, p=0.016. EQ-5D was weakly correlated with DAS-28-CRP (r=-0.32; p<0.001), moderately correlated with patient’s global assessment of disease activity (r=-0.54; p<0.001) and pain-visual analogue scale (pain-VAS) scores (r=-0.58; p<0.001) and strongly with Health Assessment Questionnaire (HAQ) score (r=-0.72; p< 0.001). After multivariate analysis, HAQ-score (β=-0.57 [95% CI -0.24 to -0.17]; p<0.001) and pain-VAS ((β=-0.25 [95% CI -0.003 to -0.002]; p<0.001) remained as independent predictors of EQ-5D (R2=0.56, p<0.001).Conclusion:Greater functional impairment and pain are associated with poor HRQoL in RA patients, and thus special attention must be given to treatment strategies providing the best patient-centred outcomes.References:[1]Yaghoubi et al. J Cardiovasc Thorac Res 2012;4(4):95–101.[2]José E et al. Ann Rheum Dis 2018;1118–24.[3]Smolen JS et al. Ann Rheum Dis. 2010; 69:631–637Disclosure of Interests:Ana Rita Prata: None declared, Helena Assunção: None declared, Mariana Luis: None declared, Luisa Brites: None declared, Flavio Costa: None declared, João Dinis de Freitas: None declared, Stefanie Silva: None declared, José Antonio P. da Silva Grant/research support from: Pfizer, Abbvie, Consultant of: Pfizer, AbbVie, Roche, Lilly, Novartis, Catia Duarte: None declared

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

2016 ◽  
Vol 76 (1) ◽  
pp. 203-207 ◽  
Author(s):  
Vibeke Strand ◽  
Philip Mease ◽  
Laure Gossec ◽  
Ori Elkayam ◽  
Filip van den Bosch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Patient Reported Outcomes ◽  
Life Quality ◽  
Phase Iii ◽  
Patient Reported ◽  
Related Quality ◽  
Global Disease Activity

ObjectiveTo evaluate the effect of secukinumab on patient-reported outcomes (PROs) in subjects with active psoriatic arthritis (PsA) in the FUTURE 1 study.MethodsSubjects were randomised 1:1:1 to receive intravenous (i.v.) secukinumab 10 mg/kg at weeks 0, 2 and 4 followed by subcutaneous secukinumab 150 or 75 mg every 4 weeks or matching placebo until week 24.ResultsAt week 24, subjects receiving secukinumab i.v.→150 mg or i.v.→75 mg reported greater least squares mean changes from baseline than those receiving placebo in patient global assessment of disease activity (−20.6 and −20.0 vs −7.4, respectively), patient assessment of pain (−20.8 and −20.4 vs −6.7), psoriatic arthritis quality of life (−3.5 and −3.2 vs −0.4), Dermatology Life Quality Index (−8.8 and −7.9 vs 0.7); p<0.0001 vs placebo for both secukinumab groups for above PROs and Functional Assessment of Chronic Illness Therapy-Fatigue (6.74 (p<0.05 vs placebo) and 6.03 vs 4.00); all of which well exceeded minimum clinically important differences.ConclusionsIn subjects with PsA, secukinumab treatment resulted in clinically meaningful improvements in global disease activity, pain, generic and disease-specific measures of health-related quality of life and fatigue.Trial registration numberNCT01392326; Results.

scholarly journals Improving the quality of life of patients with rheumatoid arthritis after rehabilitation irrespective of the level of disease activity

2020 ◽  
Author(s):  
Daniel Szewczyk ◽  
Teresa Sadura-Sieklucka ◽  
Beata Sokołowska ◽  
Krystyna Księżopolska-Orłowska
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Rehabilitation Program ◽  
Activity Level ◽  
Subjective Perception ◽  
Das28 Score ◽  
Comprehensive Rehabilitation ◽  
The Impact

Abstract Due to the exacerbation of the disease, the rehabilitation of patients with rheumatoid arthritis is often limited. The aim of the study was to analyze the impact of a comprehensive rehabilitation on a subjective perception of pain and quality of life in patients with rheumatoid arthritis depending on the level of disease activity. The study involved 58 women with rheumatoid arthritis aged 18–60, who underwent a 4-weeks comprehensive rehabilitation program. The assessment included the disease activity level on the DAS28 scale, pain intensity on the 10-point pain scale (VAS) and the value of the CRP protein. The HAQ-DI and KALU questionnaire were used to assess the quality of life. In both groups (group A—DAS28 < 4.2, group B—DAS28 ≥ 4.2) the statistically significant effects in decreasing the level of pain and improvement of quality of life were observed. This indicates the need and effectiveness of rehabilitation regardless of the level of activity of rheumatoid arthritis according to the DAS28 scale. There were no significant changes in the CRP protein level. In conclusion, the rehabilitation of patients with moderate to high disease activity is effective and the success of comprehensive rehabilitation is demonstrated by the decrease of the DAS28 score and the pain level reported by patients, as well as improving self-assessment of health and quality of life.

Evaluating the efficacy of intra-articular injections of platelet rich plasma (PRP) in rheumatoid arthritis patients and its impact on inflammatory cytokines, disease activity and quality of life.

2020 ◽  
Vol 16 ◽  
Author(s):  
Dalia S. Saif ◽  
Nagwa N. Hegazy ◽  
Enas S. Zahran
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Inflammatory Cytokines ◽  
Platelet Rich Plasma ◽  
Joint Inflammation ◽  
Monthly Interval ◽  
Post Injection ◽  
Tnf Α

Background: Among rheumatoid arthritis patients (RA), general disease activity is well regulated by diseasemodifying anti-rheumatic medications (DMARDS), but sometimes local inflammation still persists among a few joints. Adjuvant modern molecular interventions as Platelet Rich Plasma (PRP) with a suggested down regulating effect on inflammatory mediators has a proven effect in management of RA. We aim to evaluate the therapeutic effect of intra-articular PRP versus steroid in RA patients and their impact on inflammatory cytokines IL1B , TNF α, local joint inflammation, disease activity and quality of life (QL). Methods: Open labeled parallel randomized control clinical trial was carried out on 60 RA patients randomly divided into 2 groups, Group 1: included 30 patients received 3 intra-articular injections of PRP at monthly interval, Group 2: included 30 patients received single intra-articular injection of steroid. They were subjected to clinical, laboratory, serum IL1B and TNF α assessment at baseline and at 3, 6 months post injection. Results: Patients of both groups showed improvements in their scores of evaluating tools at 3months post injection and this improvement was persistent in the PRP group up to 6 months post injection while it was continued only for 3 months in the steroid group. Conclusions: PRP is a safe, effective and useful therapy in treating RA patients who had insufficient response and persistent pain and inflammation in just one or two joints through its down regulating effect on inflammatory cytokines IL1B, TNF α with subsequent improvement of local joint inflammation, disease activity and QL.

scholarly journals POS1455-HPR RELATIONSHIP BETWEEN PSYCHOLOGICAL FACTORS AND MEASURES OF RHEUMATOID ARTHRITIS ACTIVITY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1011.2-1011
Author(s):  
Y. Olyunin ◽  
V. Rybakova ◽  
E. Likhacheva ◽  
E. Nasonov
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Psychological Factors ◽  
Global Assessment ◽  
Activity Level ◽  
Anxiety And Depression ◽  
Tender Joint Count ◽  
Sf 36 ◽  
Patient Reported

Background:The patient-reported outcomes are important components of quantitative methods of rheumatoid arthritis (RA) activity assessment which are used to choose the appropriate drug therapy. The value of these parameters can be significantly affected not only by the inflammatory process, but also by the psychological characteristics of the patient and, in particular, by hardiness [1].Objectives:To study the relationship between psychological factors and signs of RA activity.Methods:Patients with RA who met the EULAR/ACR 2010 criteria, and observed at the V. A. Nasonova Research Institute of Rheumatology were included. Clinical examination was performed including patient global assessment (PGA), physician global assessment (PhGA), pain measurement on a visual analog scale, tender joint count (TJC), swollen joint count (SJC). The functional status was determined by HAQ, the quality of life – by SF-36 EQ-5D, the nature of pain – by painDETECT, the presence of anxiety and depression – by HADS. Patients also completed Hardiness Survey questionnaire to assess hardiness (HDS) and 3 components of the HDS – commitment (CMT), control (CT) and challenge (CLN). Disease activity was evaluated with DAS28, CDAI, and RAPID3. All patients signed informed consent to participate in the study. Analysis of the data was performed using Spearman’s rank test, Fisher exact test, qui-square and t-tests.Results:85 patients with RA were included. There were 69 women and 16 men. Mean age was 56.7±13.1 years, disease duration – 7.6±2.7 years. 72 patients were positive for rheumatoid factor, 75 – for anti-cyclic citrullinated peptide antibody. CDAI showed high activity in 15, moderate – in 37, low – in 30, and remission in 3 patients, DAS 28 – in 10, 55, 12, and 8, and RAPID3 – in 24, 25, 15, and 21, respectively. 24 patients had subclinically or clinically expressed anxiety and 15 –subclinically or clinically expressed depression (≥8 according to HADS). In 31 patients, the painDETECT questionnaire revealed possible or probable neuropathic pain. Mean HDS was 84.8±21.7, CMT – 38.9±9.2, CT – 29.4±8.6, CLN – 17.3±7.1. These values were comparable with the corresponding population data for this age group. There was a significant inverse correlation between HDS and RA activity measures, including SJC, TJC, DAS28 (p<0.05), pain, PGA, PhGA, CDAI, RAPID3, and HAQ (p<0.01). In addition, HDS and all its components positively correlated with quality of life, assessed by SF-36 and EQ-5D (p<0.01). In patients with subclinically and clinically expressed anxiety and depression, HDS, CMT, and CT were significantly lower than in patients without anxiety and depression (p<0.01), while the values of CLN in these groups did not differ significantly.Conclusion:The results of the present study suggest that low HDS may be one of the significant factors determining RA activity level because it does not allow patients to adapt adequately to a stressful situation produced by the disease.References:[1]Maddi SR. Am Psychol. 2008 Sep;63(6):563-4.Disclosure of Interests:None declared

scholarly journals FRI0651-HPR A RANDOMIZED PROSPECTIVE OPEN-LABEL CONTROLLED TRIAL COMPARING THE PERFORMANCE OF A CONNECTED MONITORING INTERFACE IN PATIENTS WITH RHEUMATOID ARTHRITIS VERSUS PHYSICAL ROUTINE MONITORING

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 929.1-930
Author(s):  
Y. M. Pers ◽  
V. Valsecchi ◽  
T. Mura ◽  
S. Aouinti ◽  
N. Filippi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Rheumatic Diseases ◽  
Tight Control ◽  
Link Type ◽  
Functional Scores ◽  
Monitoring Group ◽  
Disease Modifying

Background:Telemedicine has found wider application in chronic diseases for encouraging tight home-monitoring in order to improve patients’ outcome (Smolen et al. 2017).In previous studies, a high feasibility and high patient-satisfaction rate was found as well as the evidence for a superior or equal effectiveness of telemedicine compared to the standard face-to-face approach, however the results were weakened by some methodological biases and wide heterogeneity of interventions, thus preventing to draw definitive conclusions (Piga et al. 2017; Najm, Gossec, et al. 2019).Objectives:In rheumatoid arthritis (RA), telemedicine may allow a tight control of disease activity while reducing hospital visits. We developed a smartphone application connected with a physician’s interface to monitor RA patients. We aimed to assess the performance of this e-Health solution in comparison with routine practice in the management of patients with RA.Methods:A 6-month pragmatic, randomized, controlled, prospective, clinical trial was conducted in RA patients with high to moderate disease activity starting a new Disease Modifying Anti-Rheumatic Drug (DMARD) therapy. Two groups were established: “connected monitoring” and “conventional monitoring”. The primary outcome was the number of physical visits between baseline and 6 months. Secondary outcomes included adherence, satisfaction, changes in clinical, functional, and health status scores (SF-12).Results:Of the 94 randomized patients, 89 completed study: 44 in the “conventional monitoring” arm and 45 in the “connected monitoring” arm. The total number of physical visits between baseline and 6 month was significantly lower in the “connected monitoring” group (0.42 ± 0.58 versus 1.93 ± 0.55; p<0.05). No differences between groups were observed in the clinical and functional scores. A better quality of life for SF-12 subscores (Role-Physical, Social-Functioning and Role-Emotional) were found in the “connected monitoring” group.Conclusion:According to our results, a connected monitoring reduces the number of physical visits while maintaining a tight control of disease activity and improving quality of life in patients with RA starting a new treatment.References:[1] Najm, Aurelie, Laure Gossec, Catherine Weill, David Benoist, Francis Berenbaum, and Elena Nikiphorou. 2019. “Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review.”JMIR MHealth and UHealth7 (11): e14730.https://doi.org/10.2196/14730.[2] Piga, Matteo, Ignazio Cangemi, Alessandro Mathieu, and Alberto Cauli. 2017. “Telemedicine for Patients with Rheumatic Diseases: Systematic Review and Proposal for Research Agenda.”Seminars in Arthritis and Rheumatism47 (1): 121–28.https://doi.org/10.1016/j.semarthrit.2017.03.014.[3] Smolen, Josef S, Robert Landewe, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, et al. 2017. “EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update.”Annals of the Rheumatic Diseases76 (6): 960–77.https://doi.org/10.1136/annrheumdis-2016-210715.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document